109
Participants
Start Date
April 3, 2023
Primary Completion Date
August 6, 2024
Study Completion Date
August 6, 2024
BMS-986322
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0045, Pascoe Vale South
Local Institution - 0019, Carlton
Local Institution - 0024, Brisbane
Local Institution - 0060, Lee's Summit
Local Institution - 0057, Leawood
Local Institution - 0011, Webster
Local Institution - 0016, Los Angeles
Local Institution - 0012, Encino
Local Institution - 0002, Fremont
Local Institution - 0023, tabashi City
Local Institution - 0006, Birmingham
Local Institution - 0005, Fountain Valley
Local Institution - 0001, Los Angeles
Local Institution - 0003, Santa Ana
Local Institution - 0013, Coral Gables
Local Institution - 0056, Skokie
Local Institution - 0044, Clarksville
Local Institution - 0004, Beverly
Local Institution - 0007, Portsmouth
Local Institution - 0055, Durham
Local Institution - 0008, Cleveland
Local Institution - 0058, Rapid City
Local Institution - 0059, Dallas
Local Institution - 0062, St. John's
Local Institution - 0034, Barrie
Local Institution - 0020, Hamilton
Local Institution - 0041, London
Local Institution - 0030, Toronto
Local Institution - 0049, Sapporo
Local Institution - 0051, Fukuoka
Local Institution - 0042, Itabashi-Ku
Local Institution - 0026, Nagoya
Local Institution - 0027, Tsu
Local Institution - 0050, Hinckley
Local Institution - 0046, Leytonstone
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY